Payment overview · 2025
General Payments
$211.81
10 reported records · 9 companies
Healthcare provider profile · identity verified
Thomas L Bossi, DO
Allopathic & Osteopathic Physicians|Family Medicine · DAVISON, MI · NPI 1346342235
Verified facts
What the public records show
CMS Open Payments records show Thomas L Bossi, DO received $211.81 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.77 | 19.7% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $40.63 | 19.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.50 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.67 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.36 | 9.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.97 | 9.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.37 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.08 | 8.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.46 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.81 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $40.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 509 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 122 |
| Simvastatin | Simvastatin | 444 | 120 |
| Metoprolol Tartrate | Metoprolol Tartrate | 343 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 326 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 93 |
| Montelukast Sodium | Montelukast Sodium | 266 | 82 |
| Alprazolam | Alprazolam | 252 | 52 |
| Tramadol Hcl | Tramadol Hcl | 223 | 55 |
| Metformin Hcl | Metformin Hcl | 205 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 53 |
| Fenofibrate | Fenofibrate Nanocrystallized | 184 | 48 |
| Meloxicam | Meloxicam | 181 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 45 |
| Losartan Potassium | Losartan Potassium | 159 | 44 |
| Omeprazole | Omeprazole | 158 | 47 |
| Naproxen | Naproxen | 141 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 42 |
| Prednisone | Prednisone | 131 | 74 |
| Gabapentin | Gabapentin | 124 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 29 |
| Atenolol | Atenolol | 118 | 31 |
| Eliquis | Apixaban | 114 | 35 |
| Glipizide | Glipizide | 113 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 47 |
| Allopurinol | Allopurinol | 106 | 31 |
| Furosemide | Furosemide | 106 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 22 |
| Potassium Chloride | Potassium Chloride | 68 | 27 |
| Diazepam | Diazepam | 66 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | 17 |
| Alendronate Sodium | Alendronate Sodium | 59 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 32 |
| Gemfibrozil | Gemfibrozil | 54 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 20 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Temazepam | Temazepam | 48 | 12 |
| Sertraline Hcl | Sertraline Hcl | 47 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 11 |
| Ibuprofen | Ibuprofen | 45 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 11 |
| Famotidine | Famotidine | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Carvedilol | Carvedilol | 37 | 11 |
| Levemir Flexpen | Insulin Detemir | 35 | 11 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Fluconazole | Fluconazole | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 12 |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Finasteride | Finasteride | 31 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 30 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | 11 |
| Torsemide | Torsemide | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Prolia | Denosumab | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $211.81 · 10 records | GlaxoSmithKline, LLC. | AREXVY, BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, Kerendia, LifeVest, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error